Descripción de la oferta
The contract is part of the current regional call for postdoctoral researcher positions.
PROJECTS TO BE COORDINATED BY THE POSTDOCTORAL RESEARCHER:
“Discovering chronic inflammation biomarkers the define key stages in the Healthy-to-NASH (non-alcoholic steatohepatitis) transition to inform early prevention and treatment strategies” (Halt-RONIN)
HORIZON-HLTH-2022-STAY-HLTH-02
“Identificación de los cirRNA y lncRNA que regulan la firma de miRNA de respuesta al tratamiento en pacientes con hepatocarcinoma avanzado. Desarrollo de una herramienta experimental” Entidad financiadora: Instituto de Salud Carlos III (PI22/00857)
INSTITUTE OF HEALTH CARLOS III
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer being globally recognized as the fourth cause of cancer-related death that will lead more than a million annual deaths in 2030. The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is predicted to increase up to 56% in most the European countries, USA and China within the next 10 years which will dramatically impact HCC cases in the following years. The progression of the disease to proinflammatory state or metabolic dysfunction-associated steatohepatitis (MASH) leading to HCC has unique molecular and immune traits compared with other etiologies. The major actual concern is to establish reliable biomarkers that allow clinicians and patients to prevail the progression of the disease to HCC. The project is focused on the identification, characterization and validation of reliable biomarkers in extracellular vesicles (EVs), including those previously identified by members of the Consortium, useful to develop an algorithm addressed to all stakeholders in order to prevail the prognosis of malignancy in patients with liver advanced fibrosis. The molecular characterization includes cell-cell interactions and extracellular matrix pattern of the microenvironment, DNA mutations, epigenetic signature including DNA modifications and lncRNA/miRNA/circRNA signature, and metabolic profiles. Different in vitro and in vivo models will be developed for the identification of the functional relevance of EVs. The selected relevant biomarkers will be integrated in a signaling networking pattern to potential identified upstream markers, and integrated all together into artificial Intelligence (AI) tools useful for patients, health system and facultative for the best rational, economic and clinical making decisions.
Presentación de solicitudes
FOR ADDITIONAL INFORMATION OF INTERESTED CANDIDATES PLEASE CONTACT:
Dr. Jordi Muntané Relat
Laboratory 209 (Institute of Biomedicine of Seville, IBiS)
Phone: 955923122 ; e-mail: jmuntane-ibis@us.es
DEADLINE FOR PROPOSALS:
Presentation deadline for participants: March 18, 2024